These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16266989)

  • 21. Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer.
    Morrison LE; Jewell SS; Usha L; Blondin BA; Rao RD; Tabesh B; Kemper M; Batus M; Coon JS
    Genes Chromosomes Cancer; 2007 Apr; 46(4):397-405. PubMed ID: 17243161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Involvement of tyrosine phosphorylation of p185(c-erbB2/neu) in tumorigenicity induced by X-rays and the neu oncogene in human breast epithelial cells.
    Kang KS; Sun W; Nomata K; Morita I; Cruz A; Liu CJ; Trosko JE; Chang CC
    Mol Carcinog; 1998 Apr; 21(4):225-33. PubMed ID: 9585252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer.
    Dressman MA; Baras A; Malinowski R; Alvis LB; Kwon I; Walz TM; Polymeropoulos MH
    Cancer Res; 2003 May; 63(9):2194-9. PubMed ID: 12727839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer.
    Savinainen KJ; Saramäki OR; Linja MJ; Bratt O; Tammela TL; Isola JJ; Visakorpi T
    Am J Pathol; 2002 Jan; 160(1):339-45. PubMed ID: 11786427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p27Kip1 repression of ErbB2-induced mammary tumor growth in transgenic mice involves Skp2 and Wnt/beta-catenin signaling.
    Hulit J; Lee RJ; Li Z; Wang C; Katiyar S; Yang J; Quong AA; Wu K; Albanese C; Russell R; Di Vizio D; Koff A; Thummala S; Zhang H; Harrell J; Sun H; Muller WJ; Inghirami G; Lisanti MP; Pestell RG
    Cancer Res; 2006 Sep; 66(17):8529-41. PubMed ID: 16951165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.
    Landis MD; Seachrist DD; Montañez-Wiscovich ME; Danielpour D; Keri RA
    Oncogene; 2005 Aug; 24(33):5173-90. PubMed ID: 15897883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of ErbB2 enhances ethanol-stimulated intracellular signaling and invasion of human mammary epithelial and breast cancer cells in vitro.
    Ma C; Lin H; Leonard SS; Shi X; Ye J; Luo J
    Oncogene; 2003 Aug; 22(34):5281-90. PubMed ID: 12917629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis.
    Julien SG; Dubé N; Read M; Penney J; Paquet M; Han Y; Kennedy BP; Muller WJ; Tremblay ML
    Nat Genet; 2007 Mar; 39(3):338-46. PubMed ID: 17259984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A recurring pattern of chromosomal aberrations in mammary gland tumors of MMTV-cmyc transgenic mice.
    Weaver ZA; McCormack SJ; Liyanage M; du Manoir S; Coleman A; Schröck E; Dickson RB; Ried T
    Genes Chromosomes Cancer; 1999 Jul; 25(3):251-60. PubMed ID: 10379871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.
    D'Amico M; Wu K; Di Vizio D; Reutens AT; Stahl M; Fu M; Albanese C; Russell RG; Muller WJ; White M; Negassa A; Lee HW; DePinho RA; Pestell RG
    Cancer Res; 2003 Jun; 63(12):3395-402. PubMed ID: 12810676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells.
    Tari AM; Hung MC; Li K; Lopez-Berestein G
    Oncogene; 1999 Feb; 18(6):1325-32. PubMed ID: 10022814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
    Liu B; Ordonez-Ercan D; Fan Z; Edgerton SM; Yang X; Thor AD
    Int J Cancer; 2007 May; 120(9):1874-82. PubMed ID: 17266042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene copy mapping of the ERBB2/TOP2A region in breast cancer.
    Jacobson KK; Morrison LE; Henderson BT; Blondin BA; Wilber KA; Legator MS; O'Hare A; Van Stedum SC; Proffitt JH; Seelig SA; Coon JS
    Genes Chromosomes Cancer; 2004 May; 40(1):19-31. PubMed ID: 15034864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [DNA structural features on the borders of ERBB2 amplicons in breast cancer].
    Matsenko NIu; Kovalenko SP
    Mol Biol (Mosk); 2013; 47(5):818-27. PubMed ID: 25509354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.
    Miller JK; Shattuck DL; Ingalla EQ; Yen L; Borowsky AD; Young LJ; Cardiff RD; Carraway KL; Sweeney C
    Cancer Res; 2008 Oct; 68(20):8286-94. PubMed ID: 18922900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Susceptibility loci affecting ERBB2/neu-induced mammary tumorigenesis in mice.
    Quan L; Dittmar A; Zhou Y; Hutson A; Stassen AP; Demant P
    Genes Chromosomes Cancer; 2012 Jul; 51(7):631-43. PubMed ID: 22419448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
    Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
    Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
    Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL
    Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions.
    Spangenberg C; Lausch EU; Trost TM; Prawitt D; May A; Keppler R; Fees SA; Reutzel D; Bell C; Schmitt S; Schiffer IB; Weber A; Brenner W; Hermes M; Sahin U; Türeci O; Koelbl H; Hengstler JG; Zabel BU
    Cancer Res; 2006 Apr; 66(7):3715-25. PubMed ID: 16585198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.